• HARIKRISHNAN N Faculty of Pharmacy, Dr. M. G. R. Educational and Research Institute, Chennai, Tamil Nadu, India.
  • ANAS S MOHAMIED Faculty of Pharmacy, Omar Al Mukthar University, Al-Bayda, Libya.
  • GEJALAKSHMI S Faculty of Pharmacy, Dr. M. G. R. Educational and Research Institute, Chennai, Tamil Nadu, India.


Objective: Nanotechnology techniques are a creation and exploitation of materials, devices, and systems through the control of matter on the nanometer length scale, i.e., involvement of atoms, molecules, and supramolecular structures. Every existing treatment modalities against human immunodeficiency virus (HIV) offer a marginal increase in the life expectancy as chitosan was converted to its derivative aminoethyl chitosan by chemical method evaluated for anti-HIV activity.

Methods: Isolation of chitosan from crab shell by chemical method involves four basic steps; protein separation, calcium carbonate separation, deproteinization, and demineralization.

Results: The results revealed the anti-HIV activity of the prepared nanoparticulate system. Cytotoxicity assay of the nanoparticulate system was carried out and the cytotoxic concentration 50% (CC50) value was found to be 38.07±1.42 μg/ml, indicating that the nanoparticulate system is not cytotoxic. HIV-1 infection inhibition assay was carried out and the nanoparticulate system showed excellent inhibitory activity with a half-maximal inhibitory concentration (IC50) value of 3.75±0.57 μg/ml.

Conclusions: It concludes, the CC50 and inhibitory concentration 50% IC50 values, the selectivity index of the nanoparticle was found to be 17.65 compared to the standard drug nevirapine (82.32), indicating the usefulness of the formulated nanoparticulate system as potential anti-HIV agent.

Keywords: Drug delivery, Nanoparticle, Marinesource


1. Vo TS, Kim SK. Potential anti-HIV agents from marine resources: An overview. Mar Drugs 2010;8:2871-92.
2. Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, et al. Emerging nanotechology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010;5:269-85.
3. AIDS. The HIV Life Cycle; 2015.
4. National Institute of Allergy and Infectious Diseases. National Institute of Allergey and Infectious Diseases “How HIV Causes AIDS”. Maryland: National Institute of Allergy and Infectious Diseases; 2009.
5. Arbia W, Arbia L, Adour L, Amrane A. Chitin extraction from crustacean shells using biological methods-a review. Food Tech Biotechnol 2013;51:12-25.
6. Cheung RC, Ng TB, Wong JH, Chan WY. Chitosan: An update on potential biomedical and pharmaceutical applications. Mar Drugs 2015;13:5156-86.
7. Chandy T, Sharma CP. Chitosan-as a biomaterial. Biomater Artif Cells Artif Organs 1990;18:1-24. Venkatesan J, Kim SK. Chitosan composites for bone tissue engineering-An overview. Mar Drugs 2010;8:2252-66.
8. Kumar MN, Muzzarelli RA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004;104:6017-84.
9. Islam MM, Masum SM, Rahman MM, Molla MA, Shaikh AA, Roy SK. Preparation chitosan from shrimp shells and investigation of its properties. Int J Basic Appl Sci 2011;11:116-30.
10. Li Q, Dunn T, Grandmaison EW, Goosen MF. Applications and properties of chitosan. J Bioact Compat Polym 1992;7:370-97.
11. Knaul JZ, Hudson SM, Creber KA. Properties of chitin and chitosan polymers. J Polym Sci 1999;72:1079-94.
12. He G, Wang Z, Zheng H, Yin Y, Xiong X, Lin R. Preparation, characterization and properties of aminoethyl chitin hydrogels. Carbohydr Polym 2012;90:1614-9.
13. Silva TM, Alves LG, Queiroz KC, Rocha HA, Leite EL. Partial characterization and anticoagulant activity of a heterofucan from the brown seaweed Padina gymnospora. Braz J Med Biol Res 2005;38:523-33.
14. Nirmala MJ, Shiny PJ, Ernest V, Dhas SP, Samundeeswari A, Mukherjee A, et al. A review on safer means of nanoparticle synthesis by exploring the profilic marine ecosystem as a new thrust area in nanopharmaceutics. Int J Pharm Pharm Sci 2012;5:23-39.
15. Tiruwa R. A review on nanoparticles-preparation and evaluation parameters. Indian J Pharm Biol Res 2016;9:555.
16. Murugesan V, Prabhakar YS, Katti SB. CoMFA and CoMSIA studies on thiazolidine-4-one as anti-HIV-1 agents. J Mol Graph Model 2009;27:735-43.
17. Rawal RK, Tripathi R, Kulkarni S, Paranjape R, Katti SB, Pannecoque C, et al. 2-(2,6-Dihalo-phenyl)-3-heteroaryl-2- ylmethyl-1, 3-thiazolidine-4ones: Anti-HIV agents. Chem Biol Drug Des 2008;72:147-54.
18. Rengasamy S, Thangaprakasam U, et al. Isolation, screening and determination of ?-amylase activity from marine Streptomyces species. Int J Pharm Pharm Sci 2017;10:122-7.
254 Views | 147 Downloads
How to Cite
N, H., A. S MOHAMIED, and G. S. “DEVELOPMENT OF NANOPARTICULATE DRUG DELIVERY SYSTEM FROM MARINE SOURCE AGAINST HUMAN IMMUNODEFICIENCY VIRUS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 1, Nov. 2019, pp. 38-40, doi:10.22159/ajpcr.2020.v13i1.35725.
Original Article(s)